Korean J Urol.  2015 Dec;56(12):845-846. 10.4111/kju.2015.56.12.845.

Letter to the editor: Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia

• Kadihasanoglu M
• Ozbek E

• KMID: 2359878
• DOI: http://doi.org/10.4111/kju.2015.56.12.845

Abstract

No abstract available.

MeSH Terms

Humans
*Metabolic Syndrome X
*Prostatic Hyperplasia

Reference

1. Cyrus A, Kabir A, Goodarzi D, Talaei A, Moradi A, Rafiee M, et al. Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia. Korean J Urol. 2014; 55:814–820.

2. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002; 168:599–604.

3. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015; 67:1099–1109.

4. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992; 327:1185–1191.